US FDA probes tumour risk tied to Novartis gene therapy
Detailed summary
ZURICH: The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated wit ...
The Swiss drugmaker Novartis earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug
Novartis said that it had received nine reports overall of tumours in patients previously treated with Zolgensma since the therapy was first approved in 2019. The logo of Swiss drugmaker Novartis for illustrative purposes. (Reuters)
Opening of the article, excerpted from Emirates 24/7. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.emirates247.com)
